1 / 24

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

<br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. Presented By Christopher Sweeney at 2014 ASCO Annual Meeting. A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer.

kolton
Download Presentation

Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. <br /><br />E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  2. A Quick Review of the History of Hormone Sensitive Metastatic Prostate Cancer Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  3. Early Chemo+ADT: A debate in one slide – a need for randomized phase 3 trial Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  4. The CHAARTED Hypothesis Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  5. E3805 – CHAARTED Treatment Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  6. Key Eligibility Criteria Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  7. Study Endpoints Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  8. Statistical Design: History of CHAARTED<br />Intent to treat analysis, 80% power 1-sided alpha=2.5% to detect 33% improvement in median OS (with all versions) Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  9. Results: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  10. Patient characteristics Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  11. Patient characteristics Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  12. Patient characteristics Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  13. Primary endpoint: Overall survival Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  14. Causes of Death Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  15. OS by extent of metastatic disease at start of ADT Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  16. ADT + Docetaxel benefited all subgroups Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  17. Secondary Endpoints Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  18. Therapy beyond progression Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  19. Chemotherapy Doses Given Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  20. Non-Hematologic Toxicity (%) Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  21. Hematologic Toxicity (%) Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  22. Conclusion Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  23. Clinical interpretation Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

  24. Designed and conducted by: Presented By Christopher Sweeney at 2014 ASCO Annual Meeting

More Related